IRIS Accounts Production v25.3.0.601 04024474 Board of Directors 1.4.24 31.3.25 31.3.25 false true false false true false Fair value model Ordinary A 1.00000 Ordinary B 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 04024474 2024-03-31 04024474 2025-03-31 04024474 2024-04-01 2025-03-31 04024474 2023-03-31 04024474 2023-04-01 2024-03-31 04024474 2024-03-31 04024474 ns15:EnglandWales 2024-04-01 2025-03-31 04024474 ns14:PoundSterling 2024-04-01 2025-03-31 04024474 ns10:Director1 2024-04-01 2025-03-31 04024474 ns10:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 04024474 ns10:SmallEntities 2024-04-01 2025-03-31 04024474 ns10:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 04024474 ns10:SmallCompaniesRegimeForDirectorsReport 2024-04-01 2025-03-31 04024474 ns10:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 04024474 ns10:FullAccounts 2024-04-01 2025-03-31 04024474 ns10:OrdinaryShareClass1 2024-04-01 2025-03-31 04024474 ns10:OrdinaryShareClass2 2024-04-01 2025-03-31 04024474 ns10:Director2 2024-04-01 2025-03-31 04024474 ns10:CompanySecretary1 2024-04-01 2025-03-31 04024474 ns10:RegisteredOffice 2024-04-01 2025-03-31 04024474 ns5:CurrentFinancialInstruments 2025-03-31 04024474 ns5:CurrentFinancialInstruments 2024-03-31 04024474 ns5:ShareCapital 2025-03-31 04024474 ns5:ShareCapital 2024-03-31 04024474 ns5:SharePremium 2025-03-31 04024474 ns5:SharePremium 2024-03-31 04024474 ns5:CapitalRedemptionReserve 2025-03-31 04024474 ns5:CapitalRedemptionReserve 2024-03-31 04024474 ns5:RetainedEarningsAccumulatedLosses 2025-03-31 04024474 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 04024474 ns5:NetGoodwill 2024-04-01 2025-03-31 04024474 ns5:IntangibleAssetsOtherThanGoodwill 2024-04-01 2025-03-31 04024474 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-03-31 04024474 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-03-31 04024474 ns10:OrdinaryShareClass1 2025-03-31 04024474 ns10:OrdinaryShareClass2 2025-03-31 04024474 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 04024474 ns5:SharePremium 2024-03-31 04024474 ns5:CapitalRedemptionReserve 2024-03-31 04024474 ns5:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 04024474 ns10:Director1 1 2024-03-31 04024474 ns10:Director1 1 2023-03-31 04024474 ns10:Director1 1 2024-04-01 2025-03-31 04024474 ns10:Director1 1 2023-04-01 2024-03-31 04024474 ns10:Director1 1 2025-03-31 04024474 ns10:Director1 1 2024-03-31 04024474 2 ns10:Director2 2024-03-31 04024474 2 ns10:Director2 2023-03-31 04024474 2 ns10:Director2 2024-04-01 2025-03-31 04024474 2 ns10:Director2 2023-04-01 2024-03-31 04024474 2 ns10:Director2 2025-03-31 04024474 2 ns10:Director2 2024-03-31

REGISTERED NUMBER: 04024474 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 March 2025

for

M S Pharmacy Limited

M S Pharmacy Limited (Registered number: 04024474)

Contents of the Financial Statements

for the Year Ended 31 March 2025

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 3 |

M S Pharmacy Limited

Company Information

for the Year Ended 31 March 2025

| DIRECTORS: | M Sadiq

| Z B Sadiq

| SECRETARY: | M Sadiq

| REGISTERED OFFICE: | 6 Parrys Lane

| Bristol

| Avon

| BS9 1AA

| REGISTERED NUMBER: | 04024474 (England and Wales)

| ACCOUNTANTS: | M R Dury and Co Ltd

| 51 Peaslands Road

| Sidmouth

| Devon

| EX10 9BE

M S Pharmacy Limited (Registered number: 04024474)

Balance Sheet

31 March 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Investment property | 4 | 387,047 |  | 387,047 |  |

CURRENT ASSETS

Debtors | 5 | 36,613 |  | 25,431 |  |

Cash at bank | 213,469 |  | 269,860 |  |

250,082 |  | 295,291 |  |

CREDITORS

Amounts falling due within one year | 6 | 5,090 |  | 49,969 |  |

NET CURRENT ASSETS | 244,992 |  | 245,322 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 632,039 |  | 632,369 |  |

CAPITAL AND RESERVES

Called up share capital | 7 | 501 |  | 501 |  |

Share premium | 8 | 499,000 |  | 499,000 |  |

Capital redemption reserve | 8 | 499 |  | 499 |  |

Retained earnings | 8 | 132,039 |  | 132,369 |  |

SHAREHOLDERS' FUNDS | 632,039 |  | 632,369 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 29 October 2025 and were signed on its behalf by:

M Sadiq - Director

M S Pharmacy Limited (Registered number: 04024474)

Notes to the Financial Statements

for the Year Ended 31 March 2025

1. | STATUTORY INFORMATION

| M S Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Changes in accounting policies

| The estimated useful life of goodwill is considered to be 10 years and purchased goodwill is now being amortised over this period. Previously the estimated useful life had been considered to be 20 years and had been applied to goodwill purchased in 2001. All goodwill owned by the company is now to be written off over the next 10 years.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Goodwill

| Goodwill, being the amount paid in connection with the acquisition of a business has been fully amortised in the current year.

| Intangible assets

| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Investment property

| Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

M S Pharmacy Limited (Registered number: 04024474)

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

2. | ACCOUNTING POLICIES - continued

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 2 (2024 - 10 ) .

4. | INVESTMENT PROPERTY

| Total

£ |

| FAIR VALUE

| At 1 April 2024

| and 31 March 2025 | 387,047 |  |

| NET BOOK VALUE

| At 31 March 2025 | 387,047 |  |

| At 31 March 2024 | 387,047 |  |

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Other debtors | 36,613 |  | 25,431 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade creditors | (1 | ) | 1 |  |

| Taxation and social security | 1,091 |  | 25,718 |  |

| Other creditors | 4,000 |  | 24,250 |  |

5,090 |  | 49,969 |  |

M S Pharmacy Limited (Registered number: 04024474)

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

7. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 501 | Ordinary A | 1 | 501 |  | 501 |  |

| 499 | Ordinary B | 1 | - |  | - |  |

501 |  | 501 |  |

8. | RESERVES

| Capital |

| Retained |  | Share |  | redemption |

| earnings |  | premium |  | reserve |  | Totals

£ | £ | £ | £ |

| At 1 April 2024 | 132,369 |  | 499,000 |  | 499 |  | 631,868 |  |

| Profit for the year | 170 |  | - |  | - |  | 170 |  |

| Dividends | (500 | ) | - |  | - |  | (500 | ) |

| At 31 March 2025 | 132,039 |  | 499,000 |  | 499 |  | 631,538 |  |

| During the year ended 31 March 2020 the company was reorganised and a demerger took place. The Ordinary shares were redesignated as 'A Ordinary Shares' and a new class of shares ('B Ordinary Shares') was created. 499 of the A Ordinary shares were then reclassified as B Ordinary shares leaving 501 A Ordinary shares. The two different share classes held rights over different parts of the Company's trade and assets.

| The trade and assets attributed to the B Ordinary shares were transferred to H S Pharma (Bristol) Ltd (a newco) in exchange for 499 new Ordinary £1 shares in that company - a distribution in specie.

| The 499 B Ordinary shares in M S Pharmacy Ltd were then purchased by the company and subsequently cancelled.

9. | DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

| The following advances and credits to directors subsisted during the years ended 31 March 2025 and 31 March 2024:

2025 | 2024 |

£ | £ |

| M Sadiq

| Balance outstanding at start of year | 24,217 |  | - |  |

| Amounts advanced | - |  | 24,217 |  |

| Amounts repaid | (24,217 | ) | - |  |

| Amounts written off | - |  | - |  |

| Amounts waived | - |  | - |  |

| Balance outstanding at end of year | - |  | 24,217 |  |

| Z B Sadiq

| Balance outstanding at start of year | - |  | - |  |

| Amounts advanced | 36,491 |  | - |  |

| Amounts repaid | - |  | - |  |

| Amounts written off | - |  | - |  |

| Amounts waived | - |  | - |  |

| Balance outstanding at end of year | 36,491 |  | - |  |

M S Pharmacy Limited (Registered number: 04024474)

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

9. | DIRECTORS' ADVANCES, CREDITS AND GUARANTEES - continued

| The overdrawn directors loan was repaid to the company within 9 months of the year end date.